263 related articles for article (PubMed ID: 8569729)
41. N-terminal N-myristoylation of proteins: prediction of substrate proteins from amino acid sequence.
Maurer-Stroh S; Eisenhaber B; Eisenhaber F
J Mol Biol; 2002 Apr; 317(4):541-57. PubMed ID: 11955008
[TBL] [Abstract][Full Text] [Related]
42. Analyzing the substrate specificity of Saccharomyces cerevisiae myristoyl-CoA:protein N-myristoyltransferase by co-expressing it with mammalian G protein alpha subunits in Escherichia coli.
Duronio RJ; Rudnick DA; Adams SP; Towler DA; Gordon JI
J Biol Chem; 1991 Jun; 266(16):10498-504. PubMed ID: 1903791
[TBL] [Abstract][Full Text] [Related]
43. Genetic and biochemical studies establish that the fungicidal effect of a fully depeptidized inhibitor of Cryptococcus neoformans myristoyl-CoA:protein N-myristoyltransferase (Nmt) is Nmt-dependent.
Lodge JK; Jackson-Machelski E; Higgins M; McWherter CA; Sikorski JA; Devadas B; Gordon JI
J Biol Chem; 1998 May; 273(20):12482-91. PubMed ID: 9575206
[TBL] [Abstract][Full Text] [Related]
44. N-myristoyl transferase assay using phosphocellulose paper binding.
King MJ; Sharma RK
Anal Biochem; 1991 Dec; 199(2):149-53. PubMed ID: 1725948
[TBL] [Abstract][Full Text] [Related]
45. Association of NMT2 with the acyl-CoA carrier ACBD6 protects the N-myristoyltransferase reaction from palmitoyl-CoA.
Soupene E; Kao J; Cheng DH; Wang D; Greninger AL; Knudsen GM; DeRisi JL; Kuypers FA
J Lipid Res; 2016 Feb; 57(2):288-98. PubMed ID: 26621918
[TBL] [Abstract][Full Text] [Related]
46. The structure of myristoyl-CoA:protein N-myristoyltransferase.
Bhatnagar RS; Fütterer K; Waksman G; Gordon JI
Biochim Biophys Acta; 1999 Nov; 1441(2-3):162-72. PubMed ID: 10570244
[TBL] [Abstract][Full Text] [Related]
47. Heteroatom-substituted fatty acid analogs as substrates for N-myristoyltransferase: an approach for studying both the enzymology and function of protein acylation.
Heuckeroth RO; Glaser L; Gordon JI
Proc Natl Acad Sci U S A; 1988 Dec; 85(23):8795-9. PubMed ID: 3143109
[TBL] [Abstract][Full Text] [Related]
48. In vivo modulation of N-myristoyltransferase activity by orthovanadate.
King MJ; Pugazhenthi S; Khandelwal RL; Sharma RK
Mol Cell Biochem; 1995 Dec 6-20; 153(1-2):151-5. PubMed ID: 8927031
[TBL] [Abstract][Full Text] [Related]
49. Crystal structures of Saccharomyces cerevisiae N-myristoyltransferase with bound myristoyl-CoA and inhibitors reveal the functional roles of the N-terminal region.
Wu J; Tao Y; Zhang M; Howard MH; Gutteridge S; Ding J
J Biol Chem; 2007 Jul; 282(30):22185-94. PubMed ID: 17513302
[TBL] [Abstract][Full Text] [Related]
50. Detection of myristoyl CoA:protein N-myristoyltransferase activity by ion-exchange chromatography.
Paige LA; Chafin DR; Cassady JM; Geahlen RL
Anal Biochem; 1989 Sep; 181(2):254-8. PubMed ID: 2817389
[TBL] [Abstract][Full Text] [Related]
51. Metabolic activation of 2-substituted derivatives of myristic acid to form potent inhibitors of myristoyl CoA:protein N-myristoyltransferase.
Paige LA; Zheng GQ; DeFrees SA; Cassady JM; Geahlen RL
Biochemistry; 1990 Nov; 29(46):10566-73. PubMed ID: 2271666
[TBL] [Abstract][Full Text] [Related]
52. Immunocytochemical characterization and subcellular localization of human myristoyl-CoA: protein N-myristoyltransferase in HeLa cells.
McIlhinney RA; McGlone K
Exp Cell Res; 1996 Mar; 223(2):348-56. PubMed ID: 8601412
[TBL] [Abstract][Full Text] [Related]
53. Cyclohexyl-octahydro-pyrrolo[1,2-a]pyrazine-based inhibitors of human N-myristoyltransferase-1.
French KJ; Zhuang Y; Schrecengost RS; Copper JE; Xia Z; Smith CD
J Pharmacol Exp Ther; 2004 Apr; 309(1):340-7. PubMed ID: 14724220
[TBL] [Abstract][Full Text] [Related]
54. Purification and partial sequencing of myristoyl-CoA:protein N-myristoyltransferase from bovine brain.
McIlhinney RA; McGlone K; Willis AC
Biochem J; 1993 Mar; 290 ( Pt 2)(Pt 2):405-10. PubMed ID: 8452528
[TBL] [Abstract][Full Text] [Related]
55. N-Myristoylation as a Drug Target in Malaria: Exploring the Role of N-Myristoyltransferase Substrates in the Inhibitor Mode of Action.
Schlott AC; Holder AA; Tate EW
ACS Infect Dis; 2018 Apr; 4(4):449-457. PubMed ID: 29363940
[TBL] [Abstract][Full Text] [Related]
56. Selective peptidic and peptidomimetic inhibitors of Candida albicans myristoylCoA: protein N-myristoyltransferase: a new approach to antifungal therapy.
Sikorski JA; Devadas B; Zupec ME; Freeman SK; Brown DL; Lu HF; Nagarajan S; Mehta PP; Wade AC; Kishore NS; Bryant ML; Getman DP; McWherter CA; Gordon JI
Biopolymers; 1997; 43(1):43-71. PubMed ID: 9174411
[TBL] [Abstract][Full Text] [Related]
57. Use of photoactivatable peptide substrates of Saccharomyces cerevisiae myristoyl-CoA:protein N-myristoyltransferase (Nmt1p) to characterize a myristoyl-CoA-Nmt1p-peptide ternary complex and to provide evidence for an ordered reaction mechanism.
Rudnick DA; Rocque WJ; McWherter CA; Toth MV; Jackson-Machelski E; Gordon JI
Proc Natl Acad Sci U S A; 1993 Feb; 90(3):1087-91. PubMed ID: 8430078
[TBL] [Abstract][Full Text] [Related]
58. Characterization and selective inhibition of myristoyl-CoA:protein N-myristoyltransferase from Trypanosoma brucei and Leishmania major.
Panethymitaki C; Bowyer PW; Price HP; Leatherbarrow RJ; Brown KA; Smith DF
Biochem J; 2006 Jun; 396(2):277-85. PubMed ID: 16480339
[TBL] [Abstract][Full Text] [Related]
59. Novel fatty acyl substrates for myristoyl-CoA:protein N-myristoyl-transferase.
Heuckeroth RO; Jackson-Machelski E; Adams SP; Kishore NS; Huhn M; Katoh A; Lu T; Gokel GW; Gordon JI
J Lipid Res; 1990 Jun; 31(6):1121-9. PubMed ID: 2197361
[TBL] [Abstract][Full Text] [Related]
60. Myristoyl-CoA:protein N-myristoyltransferase: a novel molecular approach for cancer therapy (Review).
Selvakumar P; Pasha MK; Ashakumary L; Dimmock JR; Sharma RK
Int J Mol Med; 2002 Oct; 10(4):493-500. PubMed ID: 12239600
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
